The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
It says these may indicate a need for IV dextrose, fluid resuscitation, or cardiac monitoring, and warns against assuming worsening symptoms will resolve on their own
Elevate your wellness journey with formulations that balance tradition, science, and community success.
Ghrelin highly favors food intake
The cargo hold of an airplane can drop below freezing at cruising altitude
die Behauptung, es trage zur Behandlung einer Krankheit bei)
